Takeda Pharmaceutical Company Limited

Agouron Pharmaceuticals, Inc.

Jonathon Stuart Salsbury

Grant Jackson Palmer

Bruce Joseph Elder

Luckner Gerard Ulysse

Jeffrey Alan Stafford

Jun Feng

Stephen L Gwaltney

Zhiyuan Zhang

Paul Isbester

Yufeng Hong

Sripathy Venkatraman

Bingidimi Itute Mobele

Yuxin Zhao

Paul Kenneth Isbester

Paul R Brodfuehrer

Richard S Fornicola

Jia Liu

Maxwell M Reeve

Yi Li

Philip B Kisanga

Anand Sistla

David Paul Provencal

Todd Miller

Paul R Brodfuahrer

ZhiYuan Zhang

Paul K Isbester

The present invention relates generally to processes of making (R)-3-(2,3-Dihydroxypropyl)-6-fluoro-5-(2-fluoro-4-iodophenylamino)-8-methylpyrido[2,3-d]pyrimidine-4,7(3H,8H)-dione, intermediates thereof, and a process for making a particular polymorph of (R)-3-(2,3-Dihydroxypropyl)-6-fluoro-5-(2-fluoro-4-iodophenylamino)-8-methylpyrido[2,3-d]pyrimidine-4,7(3H,8H)-dione.

[object Object]

Compounds, pharmaceuticals, kits and methods are provided for use with DPP-IV and other S9 proteases that comprise a compound comprising: wherein M is N or CR; Qand Qare each independently selected from the group consisting of CO, SO, SO, and C&#x2550;NR; and each L, X, R, R, and Rare as defined herein.

Dipeptidyl peptidase inhibitors

Methods of making compounds of the formula (I) wherein the variables are as defined herein. Also, methods of making compounds that may be used to inhibit dipeptidyl peptidase. 

The invention relates to salts and free base forms of N,2-dimethyl-6-[7-(2-morpholinoethoxy)quinolin-4-yloxy]benzofuran-3-carboxamide. The invention further relates to pharmaceutical compositions of these salts and free base forms and methods of treating disorders such as cancer using such compositions.

Salts and polymorphs of a VEGF-R inhibitor

Growing community of inventors

Albany, NY, United States of America

Jonathon Stuart Salsbury